股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 本月底法定/註冊股本總額： HKD 20,000,000 FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 致：香港交易及結算所有限公司 公司名稱: 澳至尊國際控股有限公司 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02031 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | HKD | | 0.01 | HKD | | 20,000,000 | | 增加 / 減少 (-) | | | | | | | HK ...

Group 1 - The company reported a revenue of HKD 145 million for the six months ending September 30, 2025, representing a year-on-year increase of 14.57% [1] - The net profit for the same period was HKD 17.901 million, showing a year-on-year growth of 35.21% [1] - The basic earnings per share were HKD 0.0235 [1]

澳至尊(02031)发布截至2025年9月30日止六个月中期业绩，收益1.45亿港元，同比增长14.57%;净利润 1790.1万港元，同比增长35.21%;基本每股盈利2.35港仙。 ...

智通财经APP讯，澳至尊(02031)发布截至2025年9月30日止六个月中期业绩，收益1.45亿港元，同比增 长14.57%;净利润1790.1万港元，同比增长35.21%;基本每股盈利2.35港仙。 ...

Financial Performance - Revenue for the six months ended September 30, 2025, was HKD 144,972,000, representing a 14.6% increase from HKD 126,540,000 in the same period of 2024[3] - Gross profit for the same period was HKD 126,817,000, up from HKD 110,347,000, indicating a growth of 15.0%[3] - Profit before tax increased to HKD 21,681,000, a rise of 36.0% compared to HKD 15,939,000 in 2024[4] - Net profit for the period was HKD 17,901,000, which is a 35.5% increase from HKD 13,239,000 in the previous year[4] - Basic earnings per share rose to HKD 2.35, compared to HKD 1.74 for the same period last year, reflecting a growth of 35.0%[4] - The company reported a total comprehensive income of HKD 18,461,000 for the period, compared to HKD 14,685,000 in 2024, marking a growth of 25.5%[4] - The group recorded a net profit of HKD 17,901,000 for the six months ended September 30, 2025, compared to HKD 13,239,000 in the same period of 2024, representing a 35.5% increase[40] - Basic earnings per share for the period were HKD 2.35, up from HKD 1.74 in 2024, based on a weighted average of 762,000,000 shares[41] Revenue Breakdown - Health supplement products generated revenue of HKD 138,589,000, up from HKD 120,398,000, reflecting a growth of 15.1%[12] - Revenue from health supplement products rose by 15.1% to HKD 138,589,000, while personal care products saw a slight increase of 3.3% to HKD 5,958,000[35] - Health supplement products accounted for 95.6% of total revenue in 2025, up from 95.1% in 2024, with revenue of HKD 138,589,000[36] Assets and Liabilities - Total assets as of September 30, 2025, were HKD 201,877,000, an increase from HKD 198,722,000 as of March 31, 2025[6] - Current assets increased to HKD 162,354,000 from HKD 140,382,000, showing a growth of 15.7%[5] - Cash and cash equivalents reached HKD 82,619,000, up from HKD 78,723,000, indicating a 4.8% increase[5] - Accounts receivable increased to HKD 27,707,000 as of September 30, 2025, up from HKD 21,064,000 as of March 31, 2025[26] - The average credit period for purchases is typically 0 to 90 days, with accounts payable at HKD 2,090,000 as of September 30, 2025, compared to HKD 1,615,000 as of March 31, 2025[29] Costs and Expenses - Financing costs decreased to HKD 494,000 from HKD 562,000, a reduction of 12.1%[18] - Total tax expenses for the period were HKD 3,780,000, an increase of 40% from HKD 2,700,000 in 2024[19] - Depreciation expenses for property, plant, and equipment totaled HKD 8,640,000, an increase of 13.9% from HKD 7,584,000[22] - Sales costs increased by HKD 1,962,000 or 12.1% to HKD 18,155,000, while gross margin remained stable at 87.5% compared to 87.2% in 2024[39] Corporate Governance - The audit committee has reviewed and supervised the group's financial reporting system and internal control procedures[58] - The board of directors includes two executive directors and three independent non-executive directors, ensuring a balanced governance structure[62] - The company has complied with the corporate governance code, with the exception of the separation of roles between the chairman and CEO[55] - The company has adopted a standard code of conduct for directors regarding securities trading, with all directors confirming compliance during the period[56] - The company has not established any arrangements for directors to benefit from purchasing shares or bonds of the company or any other entity during the period[54] Strategic Initiatives - The company plans to continue optimizing its business strategy to adapt to the changing business environment[33] - The group plans to adopt digital transformation strategies to enhance operational efficiency and better understand consumer preferences[50] - The group will continue to expand product diversity to meet the preferences of different customer segments[50] Shareholder Information - The company did not declare an interim dividend for the six months ended September 30, 2025, consistent with the previous year[23] - The company has maintained a public float of at least 25% of its total issued shares throughout the period[57] - The company has not granted any stock options under the stock option plan since its adoption, resulting in no unexercised stock options as of September 30, 2025[51] - There were no repurchases of listed securities during the period, nor were there any purchases or sales of such securities by the company or its subsidiaries[52] - As of September 30, 2025, the company did not hold any treasury shares[53] - The board expresses gratitude to shareholders, business partners, and customers for their continued support[60]

Group 1 - The company, 澳至尊 (02031.HK), announced a board meeting scheduled for November 26, 2025, to consider and approve the unaudited consolidated financial results for the six months ending September 30, 2025 [1] - The board meeting will also consider the declaration of an interim dividend, if applicable [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Ausupreme International Holdings Limited 澳至尊國際控股有限公司 澳至尊國際控股有限公司（「本公司」）宣佈，本公司謹訂於二零二五年十一月二十六 日（星期三）舉行本公司董事會（「董事會」）會議，藉以（其中包括）考慮及批准本公司 及其附屬公司截至二零二五年九月三十日止六個月之未經審核綜合財務業績以供發 佈及考慮宣派中期股息（如有）。 （於開曼群島註冊成立的有限公司） 代表 澳至尊國際控股有限公司 （股份代號：2031） 主席、執行董事及聯席行政總裁 董事會會議日期 蔡志輝 香港，二零二五年十一月十三日 於本公告日期，董事會包括兩名執行董事，即蔡志輝先生（主席兼聯席行政總裁）及 何家敏女士（副主席兼聯席行政總裁）；以及三名獨立非執行董事，即陸定光教授、 尹祖伊博士及彭倩薇女士。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 澳至尊國際控股有限公司 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02031 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | HKD | | 0.01 | HKD | | 20,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 2,000,000,000 | HKD | | 0.01 | HKD | | 20,000,000 | 本月底法定/註 ...

截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 澳至尊國際控股有限公司 呈交日期: 2025年10月2日 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02031 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | HKD | | 0.01 | HKD | | 20,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 2,000,000,000 | HKD | | 0.01 | HKD | | 20,000,000 | 本月底法定/註冊 ...

Ausupreme International Holdings Limited 澳至尊國際控股有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的有限公司） （股份代號：2031） 於二零二五年九月十二日舉行之股東週年大會 按股數投票表決的結果 刊載於股東週年大會通告內所有提呈決議案已於二零二五年股東週年大會上以按 股數投票表決方式獲股東正式通過。 澳至尊國際控股有限公司之董事會（分別為「本公司」，「董事」及「董事會」）欣然公 佈，刊載於日期為二零二五年七月三十日之本公司股東週年大會（「股東週年大會」） 通告（「股東週年大會通告」）內所有提呈之普通決議案（「提呈決議案」），已於二零二 五年九月十二日（星期五）舉行之股東週年大會（「二零二五年股東週年大會」）上，以 按股數投票表決方式獲本公司普通股股份持有人（分別為「股份」及「股東」）正式通 過。 於二零二五年股東週年大會當日，總共有762,000,000股已發行股份賦予股 ...